Dianthus Therapeutics, Inc.

NASDAQ:DNTH

Biotechnology

Healthcare
$83.98 -1.25%

-$1.03 today

Market cap
$4.73B
Beta
0.07
P/E (TTM)
-343.0
EPS (TTM)
-$0.24
52W Low $16.64High $96.50

Volume 0.84M

Average 0.82M

DNTH Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Dianthus Therapeutics, Inc.NASDAQ: DNTH

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue growth accelerates

Q2 FY2026 revenue of $761K rose 294.3% year over year, ahead of the -60.8% change in trailing-twelve-month revenue. Sequentially, it rose 64.4% from the prior quarter. Over 3 fiscal years it compounded at -31.8% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 11 analysts of $2.6M (+27.7%) for the fiscal year ending Dec 2026, a step up from the -67.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$761K+64.4% QoQ
Last fiscal yearDec 2025
$2.04M-67.3% YoY
LTMJun 2026
$1.9M-60.8% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+294.3%+16.4%-277.9 pp
1 year-67.3%+27.7%+95.1 pp
3-year CAGR-31.8%+96.1%+127.9 pp
5-year CAGR+219.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
2.04M USD
Year-over-year change
-67.3%
4-year CAGR
+8.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How DNTH compares with its peers on the latest reported figures

  • DNTH's LTM Jun 2026 revenue of $1.9M is the 5th highest of the 10 companies compared; the peer median is $1.78M.
  • Its year-over-year change of -60.8% is the 2nd highest of 5, against a peer median of -79.0%.
  • Over three fiscal years its annual growth of -31.8% compares with a peer median of +100.7%.
DNTH Competitors Peer median
Revenue for DNTH and competitors
Company Period LTM YoY 3-year CAGR
ANABAnaptysBio, Inc.LTM Mar 2026$232.39M +107.7%+183.6%
QTTBQ32 Bio Inc.LTM Mar 2026$53.74M —+100.7%
ALMSAlumis Inc. Common StockLTM Jun 2026$7.4M -63.1%—
IMVTImmunovant, Inc.LTM Sep 2026$7.1M ——
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$1.9M -60.8%-31.8%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$1.78M -94.8%-70.7%
CNTBConnect Biopharma Holdings LimitedFY2025$64K -99.8%—
VERAVera Therapeutics, Inc.LTM Jun 2026$0 ——
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$0 ——
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$0 ——
Peer median (excluding DNTH) $1.78M-79.0%+100.7%

Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.48M6.42M2.83M6.24M2.04M
Cost of Revenue00000
Gross Profit1.48M6.42M2.83M6.24M2.04M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development12.61M29.38M32.84M83.11M145.64M
Selling, General & Admin1.96M6.74M18.16M24.99M34.33M
Operating Expenses14.56M36.12M51M108.1M179.97M
Depreciation & Amortization2.02M147K355K412K428K
EBITDA(11.09M)(28.33M)(43.2M)(84.56M)(161.91M)
EBITDA Margin-751.3%-441.5%-1528.7%-1356.2%-7952.3%
Operating Income(13.09M)(29.71M)(48.17M)(101.86M)(177.93M)
Operating Margin-886.6%-462.9%-1704.7%-1633.7%-8739.3%
Interest Income100K1.15M4.76M17.37M16.12M
Interest Expense00000
Other Income / Expenses(23K)1.23M4.62M16.9M15.6M
Income Before Tax(13.11M)(28.48M)(43.56M)(84.97M)(162.34M)
Pre-Tax Margin-888.1%-443.8%-1541.2%-1362.8%-7973.3%
Income Tax Expense00000
Net Income(13.11M)(28.48M)(43.56M)(84.97M)(162.34M)
Net Margin-888.1%-443.8%-1541.2%-1362.8%-7973.3%
EPS (Basic)(3.82)(7.60)(8.45)(2.55)(4.20)
EPS (Diluted)(3.82)(7.60)(8.45)(2.55)(4.20)
Weighted Avg Shares3.43M3.75M5.15M33.31M37.79M
Weighted Avg Shares (Diluted)3.43M3.75M5.15M33.31M37.79M

Dianthus Therapeutics, Inc.

NASDAQ:DNTH

Intrinsic Alpha fair value

Locked

Current Price

$83.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.